

Sub
B1

AM

8. A method of treating alcoholism and depression associated therewith comprising administering to a patient an effective amount of an opioid antagonist selected from the group consisting of nalmefene, naltrexone, nalmefene, nalorphine, nalbuphine, thebaine, levallorphan, oxymorphone, butorphanol, buprenorphine, levorphanol, meptazinol, pentazocine, dezocine, and their pharmacologically effective esters and salts, and an effective amount of an antidepressant, which antidepressant is selected from the group consisting of imipramine, amitriptyline, trimipramine, doxepin, desipramine, nortriptyline, protriptyline, amoxapine, clomipramine, maprotiline, and carbamazepine and bupropion, sertraline, fluoxetine, trazodone, and their pharmacologically effective esters and salts.
9. The method according to claim 8 wherein the opioid antagonist is naltrexone administered in an amount of from 10 to 150 mg.
10. The method according to claim 9 wherein the antidepressant is fluoxetine administered in an amount not greater than 80 mg.
11. The method according to claim 10 wherein fluoxetine is administered in an amount of from 20 to 80 mg.

ATTORNEY DOCKET NO. 14127.0001U1
PATENT

12. The method according to claim 9 wherein fluoxetine is administered in a dosage of between 10 and 40 mg.
13. The method according to claim 8 wherein the opioid antagonist is naltrexone in an amount of 10 to 25 mg and the antidepressant is fluoxetine in an amount less than 20 mg.
14. A pharmaceutical composition comprising a pharmacologically effective amount of an opioid antagonist selected from the group consisting of nalmefene, naltrexone, nalmefene, nalorphine, nalbuphine, thebaine, levallorphan, oxymorphone, butorphanol, buprenorphine, levorphanol, meptazinol, pentazocine, dezocine, and their pharmacologically effective esters and salts, and a pharmacologically effective amount of an antidepressant, which antidepressant is selected from the group consisting of imipramine, amitriptyline, trimipramine, doxepin, desipramine, nortriptyline, protriptyline, amoxapine, clomipramine, maprotiline, and carbamazepine and bupropion, sertraline, fluoxetine, trazodone, and their pharmacologically effective esters and salts.

ATTORNEY DOCKET NO. 14127.0001U1
PATENT

15. The pharmaceutical composition according to claim 14 wherein the opioid antagonist is naltrexone in an amount of 10-150 mg.
16. The composition according to claim 15 wherein the antidepressant is fluoxetine in an amount of 20-80 mg.
17. The component according to claims 15 wherein the antidepressant is fluoxetine in an amount of fluoxetine is 10-40 mg.
18. The composition according to claim 14 wherein the opioid antagonist is naltrexone present in an amount of 10-25 mg and the antidepressant is fluoxetine present in an amount less than 20 mg.
19. The pharmaceutical composition according to claim 14 wherein in opioid antagonist is nalmefene.
20. The pharmaceutical composition according to claim 14 wherein the antidepressant is sertraline.

ATTORNEY DOCKET NO. 14127.0001U1
PATENT

Sub
B3

21. A pharmaceutical kit comprising an effective pharmaceutical amount of an opioid antagonist selected from the group consisting of nalmefene, naltrexone, nalmefene, nalorphine, nalbuphine, thebaine, levallorphan, oxymorphone, butorphanol, buprenorphine, levorphanol, meptazinol, pentazocine, dezocine, and their pharmacologically effective esters and salts, and an effective pharmaceutical amount of an antidepressant, which antidepressant is selected from the group consisting of imipramine, amitriptyline, trimipramine, doxepin, desipramine, nortriptyline, protriptyline, amoxapine, clomipramine, maprotiline, and carbamazepine and bupropion, sertraline, fluoxetine, trazodone, and their pharmacologically effective esters and salts.

22. The pharmaceutical kit according to claim 21 wherein an opioid antagonist is naltrexone present in an amount of 10-150 mg.

23. The pharmaceutical kit according to claim 22 wherein the antidepressant is fluoxetine present in the amount of 20-80 mg.

24. The pharmaceutical lab according to claim 22 wherein the antidepressant is fluoxetine present in more than one dosage, each dosage having an amount of 10-40 mg.